The Impact of Statin Use on the Risk of Diabetic Polyneuropathy in Patients with Type 2 Diabetes and Hypercholesterolemia: A Multicenter Global Retrospective Cohort Study
Filipi Andreão1, Filipe Ribeiro2, Murilo Mancilha3, Gabriel Cunha4, Davi Coelho5, Matheus Pereira6, Savio Batista1, Carolina Moura7, Diogo Haddad Santos8
1Federal University of Rio de Janeiro, 2Barão de Mauá University Center, 3Anhembi Morumbi University, 4Fametro University Center, 5CEUMA University, 6University of Valença, 7Hospital Universitário Antonio Pedro, 8Hospital Alemão Oswaldo Cruz
Objective:
This study aims to investigate the association of statin use with the development of diabetic polyneuropathy (DPN) in patients with type 2 diabetes mellitus (T2DM) and hypercholesterolemia.
Background:
The relationship between statin use and the risk of DPN in patients with type T2DM remains a subject of considerable clinical interest.
Design/Methods:
We conducted a retrospective cohort study utilizing the TriNetX database. Two cohorts were compared: the DMHyperco cohort, comprising patients with T2DM and hypercholesterolemia, and the DMHyperco+S cohort, comprising patients with T2DM, hypercholesterolemia, and statin use. Propensity score matching was applied to balance the cohorts based on demographics (age and sex) and clinical parameters (glucose, HbA1c, BMI, and blood pressure).
Results:
Our study included 2,264,122 patients in the DMHyperco cohort and 972,929 patients in the DMHyperco+S cohort. After propensity score matching by demographics and laboratory values, the incidence of DPN was observed in 34,344 (3.7%) patients in the DMHyperco cohort and 50,705 patients (5.6) in the DMHyperco+S cohort. Statistical analysis revealed a significant association between statin use and the incidence of DPN, with a risk ratio of 1.501 (95% CI: 1.481, 1.521). This indicates that statin use is associated with a greater risk of developing DPN.
Conclusions:
Our findings suggest that statin use in patients with T2DM and hypercholesterolemia is significantly associated with an increased risk of developing diabetic polyneuropathy. This risk highlights the need for careful consideration and monitoring of statin therapy in the management of patients with T2DM. Further research is warranted to elucidate the underlying mechanisms and to explore potential strategies to mitigate this risk.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.